Favorable Outcomes With Perioperative Immunotherapy in Resectable NSCLC
Large real-world study finds neoadjuvant and adjuvant chemoimmunotherapy improve survival in stage II–IIIA lung cancer
Topline
A nationwide retrospective cohort study of over 1,300 patients with resectable stage II–IIIA NSCLC found that perioperative chemoimmunotherapy significantly improves 18-month distant metastasis–free survival (DMFS), yet remains underused, with fewer than 30% of eligible patients receiving it.
Study Details
Non–small cell lung cancer (NSCLC) remains…
